Designing effective clinical trials in Huntington’s disease (HD) remains a significant challenge. Particularly when it comes to selecting endpoints that are sensitive, reliable, and clinically meaningful.
In a condition characterised by gradual progression and complex pathology, the ability to accurately measure change is critical. Poor endpoint selection can lead to inconclusive results, increased costs, and delays in development.
In this webinar, IXICO brings together leading experts to explore how endpoint selection can be optimised in HD clinical trials, alongside the growing role of neuroimaging in improving trial design and outcomes.
About the speakers and moderator
Jeffrey D. Long, PhD - Professor Department of Psychiatry and Biostatistics - University of Iowa
Dr. Long is Professor in the Departments of Psychiatry and Biostatistics at the University of Iowa, where his research focuses on Huntington's disease (HD). He serves as co-chair of the C-PATH HD Regulatory Science Consortium (HD-RSC) Modeling Working Group and is a member of both the HD-RSC Coordinating Committee and the HD-RSC Regulatory Science Forum. With over 16 years of experience analyzing data from large HD observational studies—including Enroll-HD, Predict-HD, and Track-HD—Dr. Long and his collaborators have developed several disease progression indices used for clinical trial enrichment. Among these is the Huntington's Disease Integrated Staging System, designed to facilitate the planning and conduct of new clinical trials.
Marina Papoutsi, Senior Biomarker Scientist - IXICO
Marina Papoutsi is a Senior Biomarker Scientist at IXICO. Prior to joining IXICO, she was a senior research fellow at the UCL Huntington’s disease centre working with Prof Sarah Tabrizi. Marina worked for 9 years as part of the neuroimaging team developing and validating neuroimaging biomarkers in HD. She is a member of the EHDN Imaging Working Group and a member of the HDYO research committee. At IXICO she is the TA lead for HD and is collaborating with KOLs to advance regulatory discussions relating to the use of imaging biomarkers in HD clinical trials.
Moderator: Robin Wolz, Chief Scientific Officer - IXICO
Robin Wolz has over 15 years of experience in the development of innovative analytics solutions in healthcare with a focus on imaging technology. Prior to IXICO, Robin held different roles at Philips in the Research and Diagnostic X-Ray divisions. Robin holds a PhD in medical imaging and computer science from Imperial College London, focused on early detection of Alzheimer's disease. He is the co-author of more than 100 publications and holds multiple patents in the field of medical imaging and AI data analytics.
Join us to gain insights into key considerations in trial planning, including how to define, what to measure, as well as an overview of the latest advances in imaging analytics.
